{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:18Z","timestamp":1790691378402,"version":"4.1.0"},"reference-count":44,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.2967\/jnumed.121.262098","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:30:56Z","timestamp":1622835056000},"page":"259-267","source":"Crossref","is-referenced-by-count":66,"title":["An Improved <sup>211<\/sup>At-Labeled Agent for PSMA-Targeted \u03b1-Therapy"],"prefix":"10.2967","volume":"63","author":[{"given":"Ronnie C.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta Ray","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Brummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"2022032309402891000_63.2.259.1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/pros.24056","article-title":"Meeting report from the Prostate Cancer Foundation PSMA Theranostics State of the Science meeting","volume":"80","author":"Miyahira","year":"2020","journal-title":"Prostate."},{"key":"2022032309402891000_63.2.259.2","doi-asserted-by":"crossref","unstructured":"Jones W Griffiths K Barata PC Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12:1367.","DOI":"10.3390\/cancers12061367"},{"key":"2022032309402891000_63.2.259.3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semradonc.2020.07.004","article-title":"The role of theranostics in prostate cancer","volume":"31","author":"O\u2019Dwyer","year":"2021","journal-title":"Semin Radiat Oncol."},{"key":"2022032309402891000_63.2.259.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2713-y"},{"key":"2022032309402891000_63.2.259.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2022032309402891000_63.2.259.6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2022032309402891000_63.2.259.7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?","volume":"46","author":"Dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032309402891000_63.2.259.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2268"},{"key":"2022032309402891000_63.2.259.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2022032309402891000_63.2.259.10","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics."},{"key":"2022032309402891000_63.2.259.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2022032309402891000_63.2.259.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"2022032309402891000_63.2.259.13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-020-05023-2","article-title":"Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC","volume":"48","author":"Ilhan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032309402891000_63.2.259.14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy: how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)."},{"key":"2022032309402891000_63.2.259.15","doi-asserted-by":"crossref","unstructured":"Kozempel J Mokhodoeva O Vlk M. Progress in targeted alpha-particle therapy: what we learned about recoils release from in\u00a0vivo generators. Molecules. 2018;23:581.","DOI":"10.3390\/molecules23030581"},{"key":"2022032309402891000_63.2.259.16","doi-asserted-by":"publisher","DOI":"10.1118\/1.1640951"},{"key":"2022032309402891000_63.2.259.17","unstructured":"Bismuth-207. U.S. Nuclear Regulatory Commission website. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/appb\/bismuth-207.html. Updated March 24, 2021. Accessed August 11, 2021."},{"key":"2022032309402891000_63.2.259.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.174300"},{"key":"2022032309402891000_63.2.259.19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2021.01.002","article-title":"Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer","volume":"94\u201395","author":"Vaidyanathan","year":"2021","journal-title":"Nucl Med Biol."},{"key":"2022032309402891000_63.2.259.20","doi-asserted-by":"crossref","unstructured":"Sessler JL Wang B Harriman A . Photoinduced energy transfer in associated but noncovalently linked Photosynthetic model system. J Am Chem Soc. 1995;117: 704--714.","DOI":"10.1021\/ja00107a014"},{"key":"2022032309402891000_63.2.259.21","doi-asserted-by":"crossref","unstructured":"Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347--357.","DOI":"10.1021\/jm800994j"},{"key":"2022032309402891000_63.2.259.22","doi-asserted-by":"crossref","unstructured":"Vaidyanathan G, White BJ, Affleck DJ, et al. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. Bioorg Med Chem. 2012;20:6929--6939.","DOI":"10.1016\/j.bmc.2012.10.025"},{"key":"2022032309402891000_63.2.259.23","first-page":"1508","article-title":"High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use","volume":"42","author":"Zalutsky","year":"2001","journal-title":"J Nucl Med."},{"key":"2022032309402891000_63.2.259.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038505"},{"key":"2022032309402891000_63.2.259.25","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"2022032309402891000_63.2.259.26","doi-asserted-by":"publisher","DOI":"10.1021\/bc2002715"},{"key":"2022032309402891000_63.2.259.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.155929"},{"key":"2022032309402891000_63.2.259.28","doi-asserted-by":"publisher","DOI":"10.1021\/jm950801q"},{"key":"2022032309402891000_63.2.259.29","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","article-title":"177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy","volume":"46","author":"Banerjee","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032309402891000_63.2.259.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256388"},{"key":"2022032309402891000_63.2.259.31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032309402891000_63.2.259.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229229"},{"key":"2022032309402891000_63.2.259.33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol."},{"key":"2022032309402891000_63.2.259.34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/cbr.2019.3055","article-title":"Realizing clinical trials with astatine-211: the chemistry infrastructure","volume":"35","author":"Lindegren","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"2022032309402891000_63.2.259.35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jlcr.3573","article-title":"Astatine","volume":"61","author":"Meyer","year":"2018","journal-title":"J Labelled Comp Radiopharm."},{"key":"2022032309402891000_63.2.259.36","doi-asserted-by":"publisher","DOI":"10.2174\/1874471010801030177"},{"key":"2022032309402891000_63.2.259.37","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1292"},{"key":"2022032309402891000_63.2.259.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(97)00230-8"},{"key":"2022032309402891000_63.2.259.39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13550-020-0600-z","article-title":"Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors","volume":"10","author":"B\u00e4ck","year":"2020","journal-title":"EJNMMI Res."},{"key":"2022032309402891000_63.2.259.40","doi-asserted-by":"publisher","DOI":"10.1162\/153535002320162750"},{"key":"2022032309402891000_63.2.259.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229393"},{"key":"2022032309402891000_63.2.259.42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejmp.2018.05.020","article-title":"Targeted alpha therapy with 212Pb or 225Ac: change in RBE from daughter migration","volume":"51","author":"Ackerman","year":"2018","journal-title":"Phys Med."},{"key":"2022032309402891000_63.2.259.43","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104030177"},{"key":"2022032309402891000_63.2.259.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1485"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:44:07Z","timestamp":1648053847000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,31]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.2967\/jnumed.121.262098"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262098","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]}}}